WILMINGTON, Del., Oct. 17, 2024 /PRNewswire/ -- IgniteData, a company focused on healthcare technology solutions, announces a new collaboration with...
In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survivalCARDIFF, UK...
In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survivalCARDIFF, UK...
MORRISTOWN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A., today announced...
PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage...
Groundbreaking Trial Reveals DIFS Increases Neural Activity and Blood Flow in the Hippocampus, Offering Hope for Alzheimer’s TreatmentHOUSTON, TX, Oct....
Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients’ eyelids Demodex blepharitis is a...
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing...
Results from Study of Oral Gildeuretinol for Geographic Atrophy Secondary to Age-Related Macular Degeneration to be Presented as Late-Breaker During...
WARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is...
-- BPT567 is the first bifunctional PD1-IL18 immunoconjugate to enter clinical development -- -- Phase 1/2a study will evaluate BPT567...
– Topline results from Phase 2a study – Nearly 60% of all patients treated with gemlapodect and 88% of patients...
-Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and...
INTEGRIS-PSC to be featured in an oral presentation on Monday, November 18 SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 (GLOBE...
WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- HMP Partners and The Patel Family LLP, leading investors in innovative healthcare...
Lead indication for ZyVersa’s Inflammasome ASC Inhibitor IC 100 is obesity with metabolic complications. WESTON, Fla., Oct. 17, 2024 (GLOBE...
Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG...
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT TrialSAN DIEGO, Oct....
Avacta Group plc ("Avacta" or "the Group" or "the Company")Avacta Expands its Pipeline with Two Novel Assets Developed Using its...